xAnts

Medical professionals are identifying a new pattern of foot-related complications among patients using the weight-loss drug Ozempic for treatment.

Emerging clinical observations

Patients prescribed semaglutide, the active ingredient in Ozempic, are increasingly reporting various neurological and vascular issues located in their extremities. These symptoms, colloquially referred to as 'Ozempic feet', involve sensations of numbness, tingling, or sharp pains in the feet and lower legs.

While the medication is widely recognised for its effectiveness in managing type 2 diabetes and supporting weight loss, these specific peripheral symptoms have emerged as a notable concern for clinicians. The presentation of these side effects varies significantly between individual patients, making a standardised diagnostic profile difficult to establish.

Potential physiological causes

Medical experts are investigating several potential mechanisms that could link semaglutide use to these sensations. Although clinical trials focused on primary metabolic outcomes, the following areas are being scrutinised:

• Neuropathic responses: Rapid changes in metabolic processes and blood glucose levels may influence nerve sensitivity.
• Vascular changes: Alterations in weight and systemic inflammation could impact blood flow to the lower extremities.
• Nutritional deficiencies: Significant weight loss associated with the medication may lead to micronutrient gaps that affect nerve health.

Doctors advise that patients experiencing these symptoms should seek medical consultation rather than discontinuing their prescribed regimen without professional guidance.

Clinical guidance for patients

Healthcare providers are urging patients to maintain detailed logs of any new sensations or physical changes. Documenting the timing of symptoms in relation to medication dosage can assist in determining whether a direct correlation exists.

Current medical consensus suggests that while these symptoms are being reported, they do not currently outweigh the established clinical benefits for the intended patient populations. However, the emergence of these reports highlights the necessity for ongoing longitudinal studies into the long-term effects of GLP-1 receptor agonists on the peripheral nervous system.